EU Trade & Access to Medicines

Access to Essential Medicines

European Union (EU) trade policy can have a significant effect on access to medicines, particularly in developing countries. The EU seeks ambitious new levels of intellectual property (IP) protection that go beyond even the international agreement on IP protection (TRIPS) in order to protect its pharmaceutical industry. However, the resulting lack of competition and high monopoly prices impede access to medicines. HAI Europe monitors EU trade-related policies and campaigns for approaches that support improved levels of public health.


23 March, 2015 (Statement) - EU trade secrets directive threat to free speech, health, environment and worker mobility

29 September, 2014 (Press Release) - Europe seeks to expand Big Pharma monopoly at expense of poor people, warn HAI Europe and Oxfam

14 July, 2014 (Press Release) - Investor-state dispute settlement in EU-US trade deal risks access to affordable medicines

24 March, 2014 (Press Release) - TTIP: Proposals by the pharmaceutical industry undermine European public policy making and public health